All In Biotech

Drug Trial Radar · NCT04806854

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)

A Single-Center, Randomized, Open-Label, Parallel Arm Study of Daily Oral LUM-201 in Naive-to-Treatment, Prepubertal Children With Idiopathic Pediatric Growth Hormone Deficiency (PGHD)

Last checked: Nov 19, 2026Latest source record: Oct 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jul 14, 2021

Primary completion

Apr 2030

Study completion Jul 2030

Sponsor

Lead sponsor
Lumos PharmaIndustry
Sponsor type
Industry
First posted
Mar 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goals of this single site trial are to study the pharmacokinetics (PK) and pharmacodynamics of LUM-201 and effects of LUM-201 administration on growth hormone release over time in children with idiopathic pediatric growth hormone deficiency (PGHD).

Conditions

  • Growth Hormone Deficiency

Interventions

  • LUM-201Drug

    Administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of Augmented Growth Hormone (GH) PulsatilityTime frame: Day 1 to Month 6
  2. Pharmacokinetics of LUM-201 and M8Time frame: Day 1 to Month 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Maternal and Child Research, University of Chile

    Santiago, Chile

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.